



(51) International Patent Classification:

C07D 271/06 (2006.01) A61P 19/02 (2006.01)
A61K 31/4245 (2006.01) A61P 29/00 (2006.01)

(21) International Application Number:

PCT/GB2020/053357

(22) International Filing Date:

23 December 2020 (23.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19219531.1 23 December 2019 (23.12.2019) EP
20162545.6 11 March 2020 (11.03.2020) EP
20189623.0 05 August 2020 (05.08.2020) EP
20205768.3 04 November 2020 (04.11.2020) EP

(71) Applicant: SITRYX THERAPEUTICS LIMITED

[GB/GB]; 101 Bellhouse Building, Magdalen Centre, The Oxford Science Park, Oxford, OX4 4GA (GB).

(72) Inventors: **COOKE, Michael Liam**; c/o Sygnature Discovery Limited, The Discovery Building Biocity, Pennyfoot Street, Nottingham Nottinghamshire NG1 1GF (GB). **COUSIN, David**; c/o Sygnature Discovery Limited, The Discovery Building Biocity, Pennyfoot Street, Nottingham Nottinghamshire NG1 1GF (GB). **FYFE, Matthew Colin Thor**; c/o Sitryx Therapeutics Limited, S10, Magdalen Centre, 1 Robert Robinson Avenue, Oxford Science Park, Oxford Oxfordshire OX4 4GA (GB). **WAUGH, Thomas Michael**; c/o Sygnature Discovery Limited, The Discovery Building Biocity, Pennyfoot Street, Nottingham Nottinghamshire NG1 1GF (GB). **AHMED, Saleh**; c/o Sygnature Discovery Limited, The Discovery Building Biocity, Pennyfoot Street, Nottingham Nottinghamshire NG1 1GF (GB). **DE SIMONE, Alessio**; c/o Sygnature Discovery Limited, The Discovery Building Biocity, Pennyfoot Street, Nottingham Nottinghamshire NG1 1GF (GB). **TEOBALD, Barry John**; c/o Sitryx Therapeutics Limited, S10, Magdalen Centre, 1 Robert Robinson Avenue, Oxford Science Park, Oxford Oxfordshire OX4 4GA (GB).

(74) Agent: **KINCH, Alison** et al.; Sagittarius IP, Marlow International, Parkway, Marlow Buckinghamshire SL7 1YL (GB).



(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES



(57) Abstract: The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein, R^{A1}, R^{A2}, R^C and R^D are as defined herein.

